Novo Nordisk A/S (BVMF:N1VO34)

Brazil · Delayed Price · Currency is BRL

31.70

+0.09 (0.28%)

At close: Dec 4, 2025

-62.01% (1Y)

Market Cap	1.16T
Revenue (ttm)	264.23B
Net Income (ttm)	86.88B
Shares Out	n/a
EPS (ttm)	19.54
PE Ratio	13.35
Forward PE	12.51
Dividend	0.87 (2.74%)
Ex-Dividend Date	Aug 15, 2025

Volume	39,662
Average Volume	44,304
Open	31.93
Previous Close	31.61
Day's Range	31.30 - 32.04
52-Week Range	28.54 - 85.36
Beta	0.35
RSI	42.27
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]

Industry Drug Manufacturers - General

Sector Healthcare

Founded 1923

Employees 77,349

Stock Exchange Brazil Stock Exchange

Ticker Symbol N1VO34

Full Company Profile

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK Financial Statements

News

There is no news available yet.